Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escherichia coli Bacterin is an inactivated bacterial vaccine developed by Hygieia Biological Laboratories for use in veterinary medicine, specifically for dairy and beef cattle. As a bacterin, it contains killed *Escherichia coli* bacteria that serve as antigens to stimulate the animal's immune system, inducing an adaptive immune response. This vaccine is designed to prevent or reduce the severity of infections caused by *E. coli*, such as coliform mastitis in dairy cows and neonatal diarrhea (scours) in calves. Hygieia Biological Laboratories specializes in tailored veterinary biologics, and this product is part of their portfolio of agricultural animal health solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Escherichia coli Bacterin.